1-5 of 5
Nathalie Danesi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 396.
https://doi.org/10.1182/blood-2018-99-115930
Published: 2018
Journal Articles

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Sam Yuen, Max S. Topp, Chiara Rusconi, Isabelle Fleury, Christopher K Arthur, Barbara Pro, MD, Giuseppe Gritti, MD PhD, Michael Crump, Katell Le Du, MD, Divya Samineni, Arijit Sinha, Elizabeth A Punnoose, Edith Szafer-Glusman, Nathalie Danesi, Adam Petrich, Martin Kornacker, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 1614.
https://doi.org/10.1182/blood-2018-99-116806
Published: 2018
Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson
Journal: Blood
Blood (2017) 130 (Supplement 1): 727.
https://doi.org/10.1182/blood.V130.Suppl_1.727.727
Published: 2017
Journal Articles

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, PhD, Britta Kehden, Michael Unterhalt, PhD, Michael Herold, Richard H van der Jagt, Ann Janssens, MD, Michael Kneba, Jiri Mayer, MD, Chris Pocock, PhD FRCPath FRCP, Nathalie Danesi, PhD, Günter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Robert E Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2016) 128 (22): 613.
https://doi.org/10.1182/blood.V128.22.613.613
Published: 2016
Journal Articles

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Christiane Pott, MD PhD, David Belada, MD PhD, Nathalie Danesi, PhD, Günter Fingerle-Rowson, MD PhD, John Gribben, MDDSc, Chris Harbron, MPhil, Eva Hoster, PhD, Brad S Kahl, MD, Kirsten Mundt, PhD, Catherine Sebban, MD, Laurie H Sehn, MD MPH, Bruce D. Cheson, MD
Journal: Blood
Blood (2015) 126 (23): 3978.
https://doi.org/10.1182/blood.V126.23.3978.3978
Published: 2015